



ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/804,679
				Filing Date	March 18, 2004
				First Named Inventor	Andrew D. SUTTON
				Art Unit	1616
				Examiner Name	G.M. Konata
Sheet	1	of	3	Attorney Docket Number	263742002802
				Confirmation Number	8165

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KG	1.	US-3,937,668-A	02-10-1976	Zolle	
	2.	US-4,830,858-A	05-16-1989	Payne et al.	
	3.	US-4,895,719-A	01-23-1990	Radhakrishnan et al.	
	4.	US-4,952,402-A	08-28-1990	Sparks et al.	
	5.	US-5,006,343-A	04-09-1991	Benson et al.	
	6.	US-5,011,678-A	04-30-1991	Wang et al.	
	7.	US-5,049,389-A	09-17-1991	Radhakrishnan	
	8.	US-5,098,893-A	03-24-1992	Franks et al.	
	9.	US-5,113,855-A	05-19-1992	Newhouse	
	10.	US-5,225,183-A	07-06-1993	Purewal et al.	
	11.	US-5,230,884-A	07-27-1993	Evans et al.	
	12.	US-5,254,330-A	10-19-1993	Ganderton et al.	
	13.	US-5,354,562-A	10-11-1994	Platz et al.	
KG	14.	US-5,458,135-A	10-17-1995	Patton et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>2</sup> -Number <sup>3</sup> -Kind Code <sup>4</sup> (if known)				
KG	15.	DE-1080265	04-21-1960	Farbenfabriken Bayer Aktiengesellschaft		
	16.	EP-0 072 046-A1	02-16-1983	Fisons plc.		
	17.	EP-0257915-A1	03-02-1988	Innovata Biomed, Ltd.		
	18.	EP-0407028-A2	01-09-1991	Fisons PLC		
	19.	EP-0582459-B1	02-09-1994	Takeda Chemical Industries, Ltd.		
	20.	EP-0655237-A1	05-31-1995	Hoeschst Aktiengesellschaft		
	21.	EP-0748213-B1	12-18-1996	Nektar Therapeutics		
	22.	EP-0773781-B1	05-21-1997	Elan Drug Delivery, Ltd.		
	23.	GB-1122284-A	08-07-1968	Altounyan et al.		
	24.	GB-1182779-A	03-04-1970	Altounyan et al.		
	25.	JP-06-100464-A	04-12-1994	Asahi Chem Ind Co Ltd.	Machine Translation	
	26.	JP-52-139789-A	11-21-1977	Microbial Chem Res Found	Abstract	
	27.	SE-9302198	06-24-1993	Astra AB		
	28.	SE-9400370	02-04-1994	Astra AB		
	29.	WO-88/08288-A1	11-03-1988	Fuisz, Richard C.		
	30.	WO-90/11756-A1	10-18-1990	Aberdeen University		
	31.	WO-90/13285-A1	11-15-1990	Enzytech, Inc.		
	32.	WO-90/13328-A1	11-15-1990	Riker Laboratories, Inc.		
KG	33.	WO-91/16882-A1	11-14-1991	Liposome Technology, Inc.		

Examiner Signature	<i>Kat M. C.</i>	Date Considered	9.14.06
--------------------	------------------	-----------------	---------

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/804,679
				Filing Date	March 18, 2004
				First Named Inventor	Andrew D. SUTTON
				Art Unit	1616
				Examiner Name	G.M. Konata
Sheet	2	of	3	Attorney Docket Number	263742002802
				Confirmation Number	8165

KG	34.	WO-91/18091-A1	11-28-1991	Quadrant Holdings Cambridge Limited	
	35.	WO-93/00951-A1	01-21-1993	Inhale, Inc.	
	36.	WO-93/10758-A1	06-10-1993	Pitman-Moore, Inc.	
	37.	WO-93/11746-A1	06-24-1993	Boehringer Ingelheim International GMBH	Abstract
	38.	WO-93/13752-A1	07-22-1993	SRI International	
	39.	WO-93/17663-A1	09-16-1993	Fisons PLC	
	40.	WO-93/23065-A1	11-25-1993	Applied Research Systems ARS Holding	
	41.	WO-94/00291-A1	01-06-1994	Fisons PLC	
	42.	WO-94/07514-A1	04-14-1994	Inhale Therapeutic Systems	
	43.	WO-94/13271-A1	06-23-1994	Aktiebolaget Astra	
	44.	WO-94-16717-A1	08-04-1994	Miris Medical Corporation	
	45.	WO-94/22423-A1	10-13-1994	Bukh Meditec A/S	
	46.	WO-95/00127-A1	01-05-1995	Astra Aktiebolag	
	47.	WO-95/00128-A1	01-05-1995	Astra Aktiebolag	
	48.	WO-95/01324-A1	01-12-1995	Glaxo Group Limited	
	49.	WO-95/11666-A1	05-04-1995	Coordinated Drug Development Ltd.	
	50.	WO-95/24183-A1	09-14-1995	Inhale Therapeutic Systems	
KG	51.	WO-95/31479-A1	11-23-1995	Inhale Therapeutic Systems, Inc.	

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
KG	52.	Broadhead, J. et al. (1992). "The Spray Drying of Pharmaceuticals," <i>Drug Development and Industrial Pharmacy</i> 18(11&12):1169-1206.		
I	53.	Broadhead, J. et al. (June 1994). "The Effect of Process and Formulation Variable on the Properties of Spray-Dried $\beta$ -Galactosidase," <i>J. Pharm. Pharmacol.</i> 46(6):458-467.		
	54.	Graham, D. T. et al. (1984). "An In-Vitro Test for the Duration of Insulin Suspension," <i>J. Pharm. Pharmacol.</i> 36(7):427-430.		
	55.	Hahn, L. et al. (1989) "Solid Surfactant Solutions Of Active Ingredients In Sugar Esters," <i>Pharmaceutical Research</i> 6(11):958-960.		
I	56.	Heubner, W. et al. (1924). "Kurze Wissenschaftliche Mitteilungen Ueber Inhalation Von Insulin," <i>Klin Wochenschrift</i> 51:2342-2343.		
	57.	Köhler, D. (1990). "Aerosols for Systemic Treatment," <i>Lunga. (Suppl.):</i> 677-684.		

Examiner Signature		Date Considered	9.14.06
--------------------	---	-----------------	---------


pa-1050123 v2

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/804,679
				Filing Date	March 18, 2004
				First Named Inventor	Andrew D. SUTTON
				Art Unit	1616
				Examiner Name	G.M. Konata
Sheet	3	of	3	Attorney Docket Number	263742002802
				Confirmation Number	8165

KG	58.	Lee, S. et al. (April 1976). "Development of an Aerosol Dosage Form Containing Insulin," <i>Journal of Pharmaceutical Sciences</i> 65(4):567-572.	
	59.	Levine, H. et al. (May 1992). "Another View of Trehalose for Drying and Stabilizing Biological Materials," <i>Biopharm</i> 5:36-40.	
	60.	Mumenthaler, M. et al. (1994). "Feasibility Study on Spray-Drying Protein Pharmaceuticals: Recombinant Human Growth Hormone and Tissue-Type Plasminogen Activator," <i>Clinical Research</i> 11(1):12-20.	
	61.	Priority document for EP0655237, German application no. DE-19934340434 filed on November 27, 1993, 9 pages.	
	62.	Schluter, K.J. et al. (1984). "Pulmonary Administration of Human Insulin in Volunteers and Type I-Diabetics," <i>Diabetes</i> 33(Suppl.) page 75A: Abstract no. 298.	
	63.	Vidgren, M. et al. (1988). "In Vitro and In Vivo Deposition of Drug Particles Inhaled From Pressurized Aerosol and Dry Powder Inhaler," Marcel Dekker, Inc., pages 2649-2665.	
	64.	Wigley, F. M. et al. (1971). "Insulin Across Respiratory Mucosae by Aerosol Delivery," <i>Diabetes</i> 20(8):552-556.	
KG	65.	Yoshida, H. et al. (May 1979). "Absorption of Insulin Delivered to Rabbit Trachea Using Aerosol Dosage Form," <i>Journal of Pharmaceutical Sciences</i> 68(5):670-671.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	9.14.06
--------------------	---	-----------------	---------

pa-1050123 v2